会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
    • 与靶蛋白结合的SH2结构域的氧化还原稳定的非磷酸化环肽抑制剂,其结合物,组合物和合成和使用方法
    • US06951915B2
    • 2005-10-04
    • US09998350
    • 2001-11-30
    • Peter P. RollerYa-Qiu LongFeng-Di T. LungC. Richter KingDajun Yang
    • Peter P. RollerYa-Qiu LongFeng-Di T. LungC. Richter KingDajun Yang
    • A61K38/00C07K7/06C07K7/56C07K7/00A61K31/00C07K7/50
    • C07K7/06A61K38/00C07K7/56
    • A compound of formula: in which L is sulfur, sulfoxide, oxygen or methylene, and a compound of formula: in which (i) aa1 is Adi and aa4 is Glu or (ii) each of aa1 and aa4 is Adi, L is sulfur, sulfoxide, oxygen or methylene, which compounds (and their conjugates) bind to an SH2 domain in a protein comprising an SH2 domain, are non-phosphorylated, are redox-stable in vivo, are characterized by an IC50 in vivo of less than about 4.0 μM with respect to the SH2 domain in Grb2, and, upon binding to the SH2 domain of Grb2, have a turn conformation. A conjugate comprising a compound as described above and a carrier agent, a composition comprising (i) a compound or a conjugate as described above and (ii) a carrier, a method of inhibiting binding of an SH2 domain in a protein comprising an SH2 domain to a target protein in an animal, wherein the SH2 domain is contacted with a target protein-binding inhibiting effective amount of a compound or a conjugate as described above, and a method of synthesizing such conjugates.
    • 下式的化合物:其中L是硫,亚砜,氧或亚甲基,以及下式的化合物:其中(i)aa 1是Adi和aa 4是 Glu或(ii)aa 1和a 4中的每一个为Adi,L为硫,亚砜,氧或亚甲基,该化合物(及其共轭物)与SH2结合 包含SH2结构域的未被磷酸化,在体内氧化还原稳定的蛋白质的结构域的特征在于体内相对于Grb2中的SH2结构域的小于约4.0μM的IC 50 并且在与Grb2的SH2结构域结合时具有转向构象。 包含如上所述的化合物和载体的缀合物,包含(i)如上所述的化合物或缀合物和(ii)载体的组合物,抑制包含SH2结构域的蛋白质中SH2结构域结合的方法 涉及一种动物中的靶蛋白,其中SH2结构域与靶蛋白结合抑制有效量的上述化合物或结合物接触,以及合成这种缀合物的方法。
    • 6. 发明授权
    • Replication deficient adenoviral TNF vector
    • 复制缺陷型腺病毒TNF载体
    • US06579522B1
    • 2003-06-17
    • US09604694
    • 2000-06-27
    • Douglas E. BroughC. Richter KingImre KovesdiJasper J. Schaible
    • Douglas E. BroughC. Richter KingImre KovesdiJasper J. Schaible
    • A01N6300
    • C12N15/86A61K38/191A61K48/00C12N2710/10343C12N2810/40
    • An adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a radiation inducible promoter operably linked to the nucleic acid sequence coding for TNF. This invention also provides an adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a spacer element of at least 15 base pairs in the E4 region of the adenoviral genome. A method of producing an adenoviral vector and a method of treating a tumor or cancer in a host comprising administering an anti-cancer or anti-tumor effective amount of the adenoviral vector of the present invention also is provided.
    • 一种腺病毒载体,其包含(a)在腺病毒基因组的E4区域缺失的腺病毒基因组,(b)编码TNF的核酸序列,和(c)与编码TNF的核酸序列可操作地连接的放射诱导型启动子。 本发明还提供了一种腺病毒载体,其包含(a)在腺病毒基因组的E4区域缺失的腺病毒基因组,(b)编码TNF的核酸序列,和(c)至少15个碱基对的间隔元件, E4区域的腺病毒基因组。 本发明提供了生产腺病毒载体的方法和治疗宿主中的肿瘤或癌症的方法,包括给予抗癌或抗肿瘤有效量的本发明的腺病毒载体。